BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verma V, Lin SH, Simone CB 2nd, Mehta MP. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol 2016;7:644-64. [PMID: 27563457 DOI: 10.21037/jgo.2016.05.06] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Pasalic D, Prajapati S, Ludmir EB, Tang C, Choi S, Kudchadker R, Frank SJ. Outcomes and Toxicities of Proton and Photon Radiation Therapy for Testicular Seminoma. Int J Part Ther 2020;7:11-20. [PMID: 33274253 DOI: 10.14338/IJPT-20-00018.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Verma V, Rwigema JM, Malyapa RS, Regine WF, Simone CB. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiotherapy and Oncology 2017;125:21-30. [DOI: 10.1016/j.radonc.2017.08.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
3 DeCesaris CM, Berger M, Choi JI, Carr SR, Burrows WM, Regine WF, Simone CB 2nd, Molitoris JK. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. J Gastrointest Oncol 2020;11:663-73. [PMID: 32953150 DOI: 10.21037/jgo-20-205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Verma V, Choi JI, Simone CB 2nd. Proton therapy for small cell lung cancer. Transl Lung Cancer Res 2018;7:134-40. [PMID: 29876312 DOI: 10.21037/tlcr.2018.04.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Verma V, Simone CB, Mishra MV. Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review. JNCI: Journal of the National Cancer Institute 2018;110:341-53. [DOI: 10.1093/jnci/djx208] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
6 Maemura K, Mataki Y, Kurahara H, Kawasaki Y, Iino S, Sakoda M, Ueno S, Arimura T, Higashi R, Yoshiura T, Shinchi H, Natsugoe S. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology 2017;17:833-8. [DOI: 10.1016/j.pan.2017.07.191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Verma V, Lin L, Simone CB 2nd. Proton Beam Therapy for Bronchogenic Adenoid Cystic Carcinoma: Dosimetry, Toxicities, and Outcomes. Int J Part Ther 2018;4:1-9. [PMID: 31773012 DOI: 10.14338/IJPT-17-00014.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kang M, Hasan S, Press RH, Yu F, Abdo M, Xiong W, Choi JI, Simone CB 2nd, Lin H. Using patient-specific bolus for pencil beam scanning proton treatment of periorbital disease. J Appl Clin Med Phys 2021;22:203-9. [PMID: 33369041 DOI: 10.1002/acm2.13134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Verma V, Simone CB, Wahl AO, Beriwal S, Mehta MP. Proton radiotherapy for gynecologic neoplasms. Acta Oncologica 2016;55:1257-65. [DOI: 10.1080/0284186x.2016.1205218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
10 Mishra MV, Aggarwal S, Bentzen SM, Knight N, Mehta MP, Regine WF. Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. International Journal of Radiation Oncology*Biology*Physics 2017;97:228-35. [DOI: 10.1016/j.ijrobp.2016.10.045] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
11 Haque W, Verma V, Butler EB, Teh BS. Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. J Gastrointest Oncol 2018;9:80-9. [PMID: 29564174 DOI: 10.21037/jgo.2017.09.12] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
12 Créhange G, Goudjil F, Krhili SL, Minsat M, de Marzi L, Dendale R. [The role of proton therapy in esophageal cancer]. Cancer Radiother 2021:S1278-3218(21)00248-1. [PMID: 34688549 DOI: 10.1016/j.canrad.2021.08.015] [Reference Citation Analysis]
13 Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39:1010428317714626. [PMID: 28671042 DOI: 10.1177/1010428317714626] [Cited by in Crossref: 209] [Cited by in F6Publishing: 224] [Article Influence: 52.3] [Reference Citation Analysis]
14 Verma V, Kusi Appiah A, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Lin C. Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. J Gastrointest Oncol 2018;9:527-35. [PMID: 29998018 DOI: 10.21037/jgo.2018.01.15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Haque W, Verma V, Bernicker E, Butler EB, Teh BS. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base. Acta Oncologica 2018;57:782-9. [DOI: 10.1080/0284186x.2017.1409435] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
16 Simone CB 2nd, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol 2020;30:253-61. [PMID: 32503791 DOI: 10.1016/j.semradonc.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
17 Adeberg S, Harrabi SB, Bougatf N, Verma V, Windisch P, Bernhardt D, Combs SE, Herfarth K, Debus J, Rieken S. Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location. Cancers (Basel) 2018;10:E401. [PMID: 30373115 DOI: 10.3390/cancers10110401] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
18 Haque W, Verma V, Butler EB, Teh BS. Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Hulshoff JB, Mul VEM, de Boer HEM, Noordzij W, Korteweg T, van Dullemen HM, Nagengast WB, Oppedijk V, Pierie JPEN, Plukker JTM. Impact of Endoscopic Ultrasonography on 18F-FDG-PET/CT Upfront Towards Patient Specific Esophageal Cancer Treatment. Ann Surg Oncol 2017;24:1828-34. [PMID: 28303427 DOI: 10.1245/s10434-017-5835-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Hasan S, Abel S, Verma V, Webster P, Arscott WT, Wegner RE, Kirichenko A, Simone CB 2nd. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. J Gastrointest Oncol 2019;10:999-1009. [PMID: 31602338 DOI: 10.21037/jgo.2019.08.03] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
21 Haefner MF, Lang K, Verma V, Koerber SA, Uhlmann L, Debus J, Sterzing F. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. Radiat Oncol 2017;12:131. [PMID: 28810885 DOI: 10.1186/s13014-017-0863-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
22 Denniston KA, Verma V, Bhirud AR, Bennion NR, Lin C. Effect of Akimbo versus Raised Arm Positioning on Breast and Cardiopulmonary Dosimetry in Pediatric Hodgkin Lymphoma. Front Oncol 2016;6:176. [PMID: 27508169 DOI: 10.3389/fonc.2016.00176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
23 Vaios EJ, Wo JY. Proton beam radiotherapy for anal and rectal cancers. J Gastrointest Oncol 2020;11:176-86. [PMID: 32175121 DOI: 10.21037/jgo.2019.04.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Jiang W, Verma V, Haque W, Moreno AC, Koshy M, Butler EB, Teh BS. Post-treatment mortality after definitive chemoradiotherapy versus resection for esophageal cancer. Diseases of the Esophagus 2020;33:doz073. [DOI: 10.1093/dote/doz073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Simone CB 2nd. First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer. J Clin Oncol 2020;38:2952-5. [PMID: 32706638 DOI: 10.1200/JCO.20.01405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
26 Verma V, Moreno AC, Lin SH. Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med 2016;5:E91. [PMID: 27775643 DOI: 10.3390/jcm5100091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
27 Moreno AC, Verma V, Hofstetter WL, Lin SH. Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. J Thorac Oncol 2017;12:1152-60. [PMID: 28455149 DOI: 10.1016/j.jtho.2017.04.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
28 Schmitz H, Rabe M, Janssens G, Bondesson D, Rit S, Parodi K, Belka C, Dinkel J, Kurz C, Kamp F, Landry G. Validation of proton dose calculation on scatter corrected 4D cone beam computed tomography using a porcine lung phantom. Phys Med Biol 2021;66. [PMID: 34293737 DOI: 10.1088/1361-6560/ac16e9] [Reference Citation Analysis]
29 Nenoff L, Matter M, Hedlund Lindmar J, Weber DC, Lomax AJ, Albertini F. Daily adaptive proton therapy - the key to innovative planning approaches for paranasal cancer treatments. Acta Oncol 2019;58:1423-8. [PMID: 31364904 DOI: 10.1080/0284186X.2019.1641217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
30 Lühr A, von Neubeck C, Pawelke J, Seidlitz A, Peitzsch C, Bentzen SM, Bortfeld T, Debus J, Deutsch E, Langendijk JA, Loeffler JS, Mohan R, Scholz M, Sørensen BS, Weber DC, Baumann M, Krause M; “Radiobiology of Proton Therapy”. "Radiobiology of Proton Therapy": Results of an international expert workshop. Radiother Oncol 2018;128:56-67. [PMID: 29861141 DOI: 10.1016/j.radonc.2018.05.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 18.0] [Reference Citation Analysis]
31 Dickmann J, Rit S, Pankuch M, Johnson RP, Schulte RW, Parodi K, Dedes G, Landry G. An optimization algorithm for dose reduction with fluence‐modulated proton CT. Med Phys 2020;47:1895-906. [DOI: 10.1002/mp.14084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
32 Haefner MF, Lang K, Verma V, Koerber SA, Uhlmann L, Debus J, Sterzing F. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer: Outcomes and patterns of failure. Strahlenther Onkol 2018;194:116-24. [DOI: 10.1007/s00066-017-1211-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
33 Haque W, Verma V, Butler EB, Teh BS. Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States. J Gastrointest Oncol 2018;9:282-94. [PMID: 29755767 DOI: 10.21037/jgo.2017.11.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Toh Y, Numasaki H, Tachimori Y, Uno T, Jingu K, Nemoto K, Matsubara H. Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society. Esophagus 2020;17:25-32. [DOI: 10.1007/s10388-019-00690-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Ryckman JM, Ganesan V, Kusi Appiah A, Zhang C, Verma V. National practice patterns of proton versus photon therapy in the treatment of adult patients with primary brain tumors in the United States. Acta Oncol 2019;58:66-73. [PMID: 30280620 DOI: 10.1080/0284186X.2018.1512755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
36 Verma V, Haque W, Zheng D, Osayande F, Lin C. Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial. Am J Clin Oncol 2019;42:67-74. [PMID: 30216194 DOI: 10.1097/COC.0000000000000481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
37 Haefner MF, Verma V, Bougatf N, Mielke T, Tonndorf-Martini E, König L, Rwigema JM, Simone CB 2nd, Uhlmann L, Eichhorn F, Winter H, Grosch H, Haberer T, Herfarth K, Debus J, Rieken S. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta Oncol 2018;57:1713-20. [PMID: 30264630 DOI: 10.1080/0284186X.2018.1502467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
38 Mizuhata M, Takamatsu S, Shibata S, Bou S, Sato Y, Kawamura M, Asahi S, Tameshige Y, Maeda Y, Sasaki M, Kumano T, Kobayashi S, Yamamoto K, Tamamura H, Gabata T. Respiratory-gated Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract without Fiducial Markers. Cancers (Basel) 2018;10:E58. [PMID: 29466294 DOI: 10.3390/cancers10020058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]